# Hugo Harrod

> Hugo Harrod is a funding round investor at MVM Life Science Partners backing Medical. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [MVM Life Science Partners](https://shizune.co/investors/profile/mvm-life-science-partners)
- Location: London, United Kingdom
- Total investments: 9
- Last investment: Aug 2025
- Lead investor: 56%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/hugo-harrod/10/106/319

Hugo Harrod is a funding round investor at MVM Life Science Partners in London focused on Medical and Health Care. Hugo Harrod is based out of London, England and is the Board of Director of ProVerum Medical. and also Partner of MVM Life Science Partners. Hugo previously worked at AccuVein as a Board Member. Hugo Harrod attended the University of Oxford.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 4 | 44% |
| Health Care | 4 | 44% |
| Medical Device | 4 | 44% |
| Biotechnology | 3 | 33% |
| Genetics | 1 | 11% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 4 | 44% |
| Series B | 2 | 22% |
| Series C | 1 | 11% |
| Series E | 1 | 11% |
| Venture - Series Unknown | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 33% |
| United Kingdom | 2 | 22% |
| Germany | 1 | 11% |
| Ireland | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ProVerum Medical | ProVerum Medical is a healthcare company that develops innovative treatments for benign prostatic hyperplasia (BPH). ProVerum develops the ProVee System, which is a minimally invasive implant that gently opens the blocked part of the urethra without cutting, heating, or removing tissue. | $80M | Series B | Aug 25, 2025 |  |
| Nalu Medical | Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people.The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS)and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California. | $85M | Series E | Jan 03, 2024 |  |
| Gynesonics | Gynesonics is a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions. Gynesonics serves customers worldwide. It was founded in 2005 and is headquartered in Redwood City, California. | $42.5M |  | Oct 25, 2023 |  |
| Nalu Medical | Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people.The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS)and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California. | $104M | Venture - Series Unknown | Feb 17, 2022 |  |
| Vertos Medical | Vertos Medical is a healthcare company that offers medical devices used in the treatment of common spinal diseases. The company commercializes the percutaneous treatment for lumbar spinal stenosis (LSS). It also offers minimally invasive lumbar decompression devices for the treatment of various forms of LSS. The company offers its devices in theUnited States. Vertos Medical was founded by Dr. Dave Solsberg and Dr. Don Schomer in 2005 and is headquartered in Aliso Viejo, California. | $28M |  | Jun 12, 2017 |  |
| Horizon Discovery | Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated acatalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12, 000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline. | $8.8M |  | Jun 03, 2013 |  |
| Horizon Discovery | Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated acatalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12, 000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline. | $14.4M | Series C | Sep 13, 2011 |  |
| Vantia Therapeutics | Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need. Its strong clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, which directly target indications that together affect many millions of people, are poorly treated and representbillion dollar markets. Vantia's strategy is to develop its proprietary drug candidates through Phase II clinical testing and then commercialise through partnerships. The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners. | $6.5M | Series B |  |  |
| eZono | eZono is a young dynamic company focused on point of care solutions. Based in Jena, Germany, eZono brings together a multicultural team of experts, bringing a diverse and fresh approach to ultrasound guidance of interventional procedures.Founded in 2004, eZono AG is a different kind of ultrasound company, one that empowers non-traditionalultrasound users to incorporate sonography in their daily work. This enables their customers to improve clinical outcomes, enhance patient satisfaction and in particular lower cost. As a result they bring not only affordable portable sonography technology to specific applications but also makes it easy for instance for anesthetists to operate – reducing drastically their learning effort. | $10M |  |  |  |

9 of 9 investments shown.

## Co-investors
- [Endeavour Vision](https://shizune.co/investors/profile/endeavour-vision) — VC Fund, 4 deals together
- [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners) — VC Fund, 3 deals together
- [Advent Life Sciences](https://shizune.co/investors/profile/advent-life) — VC Fund, 2 deals together
- [Aperture Venture Partners](https://shizune.co/investors/profile/aperture-venture-partners) — VC Fund, 2 deals together
- [Decheng Capital](https://shizune.co/investors/profile/decheng-capital) — VC Fund, 2 deals together
- [Molten Ventures](https://shizune.co/investors/profile/draper-esprit) — VC Fund, 2 deals together

## About MVM Life Science Partners

VC Fund · London, United Kingdom

MVM manages four funds totaling more than US$700 million. MVM has invested in biopharmaceuticals, diagnostics, drug delivery, gene therapy, healthcare services, medical devices, OTC medicines, research tools and vaccines.

5 contacts available at MVM Life Science Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Anna Norrington | Head of Investor Communications | https://shizune.co/investors/profile/anna-norrington |
| Hugo Harrod | Partner | https://shizune.co/investors/profile/hugo-harrod |
| Neil Akhurst | Finance Partner | https://shizune.co/investors/profile/neil-akhurst |
| Stephen Reeders | Founder & Managing Partner | https://shizune.co/investors/profile/stephen-reeders |
| Stephen Reeders | Founder & Managing Partner | https://shizune.co/investors/profile/dr-stephen-reeders |

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Hugo Harrod invest in?

Hugo Harrod invests primarily in Medical, Health Care and Medical Device startups, most often at Funding Round and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Hugo Harrod last invest?

The most recent investment recorded for Hugo Harrod closed in Aug 2025. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co